Skip to main content
PMC home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1999 Apr;52(2):55–63. doi: 10.1136/mp.52.2.55

Demystified ... oncogenes.

Y L Wallis 1, F Macdonald 1
PMCID: PMC395674  PMID: 10474682

Full Text

The Full Text of this article is available as a PDF (206.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alitalo K., Winqvist R., Lin C. C., de la Chapelle A., Schwab M., Bishop J. M. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4534–4538. doi: 10.1073/pnas.81.14.4534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988 May 20;53(4):549–554. doi: 10.1016/0092-8674(88)90571-5. [DOI] [PubMed] [Google Scholar]
  3. Amati B., Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev. 1994 Feb;4(1):102–108. doi: 10.1016/0959-437x(94)90098-1. [DOI] [PubMed] [Google Scholar]
  4. Balaban G., Herlyn M., Guerry D., 4th, Bartolo R., Koprowski H., Clark W. H., Nowell P. C. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet. 1984 Apr;11(4):429–439. doi: 10.1016/0165-4608(84)90024-4. [DOI] [PubMed] [Google Scholar]
  5. Barletta C., Lazzaro D., Prosperi Porta R., Testa U., Grignani F., Ragusa R. M., Leone R., Patella A., Carenza L., Peschle C. C-MYB activation and the pathogenesis of ovarian cancer. Eur J Gynaecol Oncol. 1992;13(1):53–59. [PubMed] [Google Scholar]
  6. Barletta C., Pelicci P. G., Kenyon L. C., Smith S. D., Dalla-Favera R. Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science. 1987 Feb 27;235(4792):1064–1067. doi: 10.1126/science.3469751. [DOI] [PubMed] [Google Scholar]
  7. Barone M. V., Courtneidge S. A. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature. 1995 Nov 30;378(6556):509–512. doi: 10.1038/378509a0. [DOI] [PubMed] [Google Scholar]
  8. Bell S. M., Scott N., Cross D., Sagar P., Lewis F. A., Blair G. E., Taylor G. R., Dixon M. F., Quirke P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993 Jan;104(1):57–64. doi: 10.1016/0016-5085(93)90835-z. [DOI] [PubMed] [Google Scholar]
  9. Bigoni R., Negrini M., Veronese M. L., Cuneo A., Castoldi G. L., Croce C. M. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene. 1996 Aug 15;13(4):797–802. [PubMed] [Google Scholar]
  10. Bos J. L. The ras gene family and human carcinogenesis. Mutat Res. 1988 May;195(3):255–271. doi: 10.1016/0165-1110(88)90004-8. [DOI] [PubMed] [Google Scholar]
  11. Brodeur G. M., Fong C. T. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet. 1989 Sep;41(2):153–174. doi: 10.1016/0165-4608(89)90243-4. [DOI] [PubMed] [Google Scholar]
  12. Caldas C., Hahn S. A., Hruban R. H., Redston M. S., Yeo C. J., Kern S. E. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994 Jul 1;54(13):3568–3573. [PubMed] [Google Scholar]
  13. Cooper G. M. Cellular transforming genes. Science. 1982 Aug 27;217(4562):801–806. doi: 10.1126/science.6285471. [DOI] [PubMed] [Google Scholar]
  14. Duesberg P. H., Vogt P. K. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci U S A. 1970 Dec;67(4):1673–1680. doi: 10.1073/pnas.67.4.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Eng C., Smith D. P., Mulligan L. M., Nagai M. A., Healey C. S., Ponder M. A., Gardner E., Scheumann G. F., Jackson C. E., Tunnacliffe A. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994 Feb;3(2):237–241. doi: 10.1093/hmg/3.2.237. [DOI] [PubMed] [Google Scholar]
  16. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  17. Field J. K., Spandidos D. A. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). Anticancer Res. 1990 Jan-Feb;10(1):1–22. [PubMed] [Google Scholar]
  18. Finkelstein S. D., Sayegh R., Bakker A., Swalsky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg. 1993 May;128(5):526–532. doi: 10.1001/archsurg.1993.01420170056008. [DOI] [PubMed] [Google Scholar]
  19. Garcia R., Parikh N. U., Saya H., Gallick G. E. Effect of herbimycin A on growth and pp60c-src activity in human colon tumor cell lines. Oncogene. 1991 Nov;6(11):1983–1989. [PubMed] [Google Scholar]
  20. Goodfellow P. J. Inherited cancers associated with the RET proto-oncogene. Curr Opin Genet Dev. 1994 Jun;4(3):446–452. doi: 10.1016/0959-437x(94)90034-5. [DOI] [PubMed] [Google Scholar]
  21. Guérin M., Sheng Z. M., Andrieu N., Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990 Jan;5(1):131–135. [PubMed] [Google Scholar]
  22. Hajj C., Akoum R., Bradley E., Paquin F., Ayoub J. DNA alterations at proto-oncogene loci and their clinical significance in operable non-small cell lung cancer. Cancer. 1990 Aug 15;66(4):733–739. doi: 10.1002/1097-0142(19900815)66:4<733::aid-cncr2820660422>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  23. Heighway J., Thatcher N., Cerny T., Hasleton P. S. Genetic predisposition to human lung cancer. Br J Cancer. 1986 Apr;53(4):453–457. doi: 10.1038/bjc.1986.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jiang W., Kahn S. M., Tomita N., Zhang Y. J., Lu S. H., Weinstein I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res. 1992 May 15;52(10):2980–2983. [PubMed] [Google Scholar]
  25. Kinzler K. W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996 Oct 18;87(2):159–170. doi: 10.1016/s0092-8674(00)81333-1. [DOI] [PubMed] [Google Scholar]
  26. Krontiris T. G., Devlin B., Karp D. D., Robert N. J., Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med. 1993 Aug 19;329(8):517–523. doi: 10.1056/NEJM199308193290801. [DOI] [PubMed] [Google Scholar]
  27. Krontiris T. G., DiMartino N. A., Colb M., Parkinson D. R. Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. 1985 Jan 31-Feb 6Nature. 313(6001):369–374. doi: 10.1038/313369a0. [DOI] [PubMed] [Google Scholar]
  28. Lammie G. A., Fantl V., Smith R., Schuuring E., Brookes S., Michalides R., Dickson C., Arnold A., Peters G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene. 1991 Mar;6(3):439–444. [PubMed] [Google Scholar]
  29. Laurent-Puig P., Olschwang S., Delattre O., Remvikos Y., Asselain B., Melot T., Validire P., Muleris M., Girodet J., Salmon R. J. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology. 1992 Apr;102(4 Pt 1):1136–1141. [PubMed] [Google Scholar]
  30. Mak Y. F., Ponder B. A. RET oncogene. Curr Opin Genet Dev. 1996 Feb;6(1):82–86. doi: 10.1016/s0959-437x(96)90015-5. [DOI] [PubMed] [Google Scholar]
  31. Moerkerk P., Arends J. W., van Driel M., de Bruïne A., de Goeij A., ten Kate J. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res. 1994 Jul 1;54(13):3376–3378. [PubMed] [Google Scholar]
  32. Moscatello D. K., Holgado-Madruga M., Godwin A. K., Ramirez G., Gunn G., Zoltick P. W., Biegel J. A., Hayes R. L., Wong A. J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995 Dec 1;55(23):5536–5539. [PubMed] [Google Scholar]
  33. Mountain C. F. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest. 1995 Jul;108(1):246–254. doi: 10.1378/chest.108.1.246. [DOI] [PubMed] [Google Scholar]
  34. Park J., Cartwright C. A. Src activity increases and Yes activity decreases during mitosis of human colon carcinoma cells. Mol Cell Biol. 1995 May;15(5):2374–2382. doi: 10.1128/mcb.15.5.2374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Portier M., Molès J. P., Mazars G. R., Jeanteur P., Bataille R., Klein B., Theillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992 Dec;7(12):2539–2543. [PubMed] [Google Scholar]
  36. Proctor A. J., Coombs L. M., Cairns J. P., Knowles M. A. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene. 1991 May;6(5):789–795. [PubMed] [Google Scholar]
  37. Rochlitz C. F., Scott G. K., Dodson J. M., Liu E., Dollbaum C., Smith H. S., Benz C. C. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res. 1989 Jan 15;49(2):357–360. [PubMed] [Google Scholar]
  38. Roth J. A. Molecular events in lung cancer. Lung Cancer. 1995 Jun;12 (Suppl 2):S3–15. doi: 10.1016/s0169-5002(10)80002-9. [DOI] [PubMed] [Google Scholar]
  39. Schwab M., Alitalo K., Klempnauer K. H., Varmus H. E., Bishop J. M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983 Sep 15;305(5931):245–248. doi: 10.1038/305245a0. [DOI] [PubMed] [Google Scholar]
  40. Schwab M., Amler L. C. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosomes Cancer. 1990 Jan;1(3):181–193. doi: 10.1002/gcc.2870010302. [DOI] [PubMed] [Google Scholar]
  41. Shih C., Shilo B. Z., Goldfarb M. P., Dannenberg A., Weinberg R. A. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5714–5718. doi: 10.1073/pnas.76.11.5714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sidransky D., Tokino T., Hamilton S. R., Kinzler K. W., Levin B., Frost P., Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992 Apr 3;256(5053):102–105. doi: 10.1126/science.1566048. [DOI] [PubMed] [Google Scholar]
  43. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  44. Slebos R. J., Kibbelaar R. E., Dalesio O., Kooistra A., Stam J., Meijer C. J., Wagenaar S. S., Vanderschueren R. G., van Zandwijk N., Mooi W. J. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990 Aug 30;323(9):561–565. doi: 10.1056/NEJM199008303230902. [DOI] [PubMed] [Google Scholar]
  45. Smith-Ravin J., England J., Talbot I. C., Bodmer W. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut. 1995 Jan;36(1):81–86. doi: 10.1136/gut.36.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Spencer C. A., Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res. 1991;56:1–48. doi: 10.1016/s0065-230x(08)60476-5. [DOI] [PubMed] [Google Scholar]
  47. Stehelin D., Varmus H. E., Bishop J. M., Vogt P. K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 1976 Mar 11;260(5547):170–173. doi: 10.1038/260170a0. [DOI] [PubMed] [Google Scholar]
  48. Tahara E. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer. 1995 Mar 15;75(6 Suppl):1410–1417. doi: 10.1002/1097-0142(19950315)75:6+<1410::aid-cncr2820751504>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  49. Tahara E., Sumiyoshi H., Hata J., Yasui W., Taniyama K., Hayashi T., Nagae S., Sakamoto S. Human epidermal growth factor in gastric carcinoma as a biologic marker of high malignancy. Jpn J Cancer Res. 1986 Feb;77(2):145–152. [PubMed] [Google Scholar]
  50. Viallet J., Minna J. D. Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Respir Cell Mol Biol. 1990 Mar;2(3):225–232. doi: 10.1165/ajrcmb/2.3.225. [DOI] [PubMed] [Google Scholar]
  51. Watson J. V., Stewart J., Evan G. I., Ritson A., Sikora K. The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer. 1986 Mar;53(3):331–337. doi: 10.1038/bjc.1986.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Weinberg R. A. Oncogenes of spontaneous and chemically induced tumors. Adv Cancer Res. 1982;36:149–163. doi: 10.1016/s0065-230x(08)60424-8. [DOI] [PubMed] [Google Scholar]
  53. Yamashita N., Minamoto T., Ochiai A., Onda M., Esumi H. Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for malignant progression? Cancer. 1995 Mar 15;75(6 Suppl):1527–1533. doi: 10.1002/1097-0142(19950315)75:6+<1527::aid-cncr2820751524>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES